Canadian approval for ZymeTx' point-of-care flu test:
This article was originally published in Clinica
ZymeTx has received the go-ahead to market its ZstatFlu test in Canada. The product allows doctors to diagnose influenza A and B in under 60 minutes. It was the first point-of-care test for influenza to receive US clearance in September 1997 (see Clinica 775, p 17).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.